Home›Psychiatry› GLP-1R exposure shows no causal link to most mental disorders except eating disorders
GLP-1R exposure shows no causal link to most mental disorders except eating disordersGLP-1 Receptor Agonists Show Mixed Links to Mental Health
Journal of affective disordersPublished June 15, 2026Study authors: Ouyang Chenhao, Zhang Xiaoyue, Zhang Minghai, Miao Yan, Zhu Zicheng, Zeng Yunting, Ban Hong, Wu Yuti…PubMed ↗DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that GLP-1R agonists show no causal link to most mental disorders except for a significant reduction in eating disorders.
This meta-analysis evaluates the causal link between Glucagon-like peptide-1 receptor (GLP-1R) and GLP-1RAs exposure and several mental health outcomes, including anxiety, bipolar affective disorders, depression, eating disorders, suicide, and schizophrenia. The study utilized two-sample Mendelian randomization to assess genetic evidence for these associations.
The analysis found no causal relationship between GLP-1R/GLP-1RAs and anxiety (OR = 0.870, P = 0.250), bipolar affective disorders (OR = 0.931, P = 1.00), chronic depression (OR = 1.012, P = 0.878), depression (OR = 0.985, P = 1.00), eating disorders (OR = 0.885, P = 1.00), suicide (OR = 1.040, P = 0.915), and schizophrenia (OR = 1.064, P = 1.00). In real-world data, no significant differences were found for suicidal ideation or behavior (OR = 0.92, P = 0.67), anxiety (OR = 1.03, P = 0.93), or depressive symptoms (SMD = -0.25, P = 0.39). However, a significant difference was noted in eating disorders (SMD = -0.71, P = 0.006) in real-world settings.
A notable limitation mentioned is that eating disorders were excluded from LDSC due to negative SNP-based heritability. These findings suggest that while GLP-1RAs may show specific effects in certain contexts like eating disorders, they do not appear to have a broad causal impact on the majority of investigated mental health conditions.
How this fits prior evidence
This meta-analysis addresses a gap regarding the causal link between GLP-1 receptor agonists and mental health outcomes. While previous evidence has identified specific interventions for anxiety and depression—such as esketamine reducing postoperative anxiety (SMD -1.23) and depressive symptoms (SMD -0.92)—this study provides genetic evidence that GLP-1R exposure does not causally impact most of these conditions, including anxiety and depression.
Researchers looked at the relationship between GLP-1 receptor agonists (GLP-1RAs) and several mental health conditions. They specifically checked for a causal link between these medications and conditions such as anxiety, depression, bipolar disorder, and schizophrenia.
The study used genetic data to see if there was a clear connection. For most conditions, including anxiety, depression, and schizophrenia, the results showed no evidence of a causal relationship. This means that based on the genetic data analyzed, these medications were not linked to changes in those specific mental health outcomes.
However, when looking at real-world data for eating disorders, the study did find a significant difference. It is important to note that this finding was specific to eating disorders and did not apply to other conditions like anxiety or depression. Because the evidence is based on complex genetic modeling and limited real-world data, these results are not yet enough to change how doctors treat patients today.
What this means for you:
The study found no genetic link between GLP-1 receptor agonists and most mental health disorders except eating disorders.
Common questions
Does this medication affect anxiety or depression?
The study looked at the genetic link between GLP-1 receptor agonists and anxiety and depression. The results showed no causal relationship for either condition. This means that, based on the genetic data analyzed in this specific study, there was no evidence that these medications caused changes in anxiety or depressive symptoms.
What did the study find regarding eating disorders?
While most mental health conditions showed no link to GLP-1 receptor agonists, the real-world data showed a significant difference for eating disorders. This specific finding suggests a different outcome for eating disorders compared to other conditions like schizophrenia or bipolar disorder.
Is it safe to take these medications if I have a mental health condition?
The study was designed to look at genetic links rather than provide safety advice. Because the evidence is based on complex models and not clinical trials, you should talk to your doctor before making any changes to your medication or treatment plan.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), recognized for hypoglycemic and weight reduction efficacy, have been debated regarding potential association with mental disorders. This study sought to elucidate causal relationship between GLP-1RAs and mental disorders.
METHOD: Two-sample Mendelian randomization, Linkage Disequilibrium Score Regression (LDSC) and Bayesian co-localization were conducted to assess causal associations between Glucagon-like peptide-1 receptor (GLP-1R) and seven mental disorders: anxiety, bipolar affective disorders, chronic depression, depression, eating disorders, suicide and schizophrenia. A meta-analysis of clinical studies was conducted between GLP-RAs use and mental health.
RESULTS: LDSC revealed no genetic associations between GLP-1R and six mental disorders (Eating disorders were excluded from LDSC due to negative SNP-based heritability). GLP-1R were not causally related to mental disorders: anxiety (OR = 0.870, P = 0.250), bipolar affective disorders (OR = 0.931, P = 1.00), chronic depression (OR = 1.012, P = 0. 878), depression (OR = 0.985, P = 1.00), eating disorders (OR = 0.885, P = 1.00), suicide (OR = 1.040, P = 0.915), schizophrenia (OR = 1.064, P = 1.00). These findings were validated using eQTLGen Consortium or Psychiatric Genomics Consortium (all P > 0.900) and corroborated by Bayesian co-localization. The meta-analysis revealed no significant difference between the GLP-1 RAs exposure group and the control group in suicidal ideation or behavior (OR = 0.92, P = 0.67), anxiety (OR = 1.03, P = 0.93), depressive symptoms (SMD = -0.25, P = 0.39), but showed a significant difference in eating disorders (SMD = -0.71, P = 0.006).
CONCLUSION: GLP-1R showed no genetic evidence linking anxiety, bipolar affective disorders, chronic depression, depression, eating disorders, suicide, and schizophrenia. The pooled results of real-world evidence showed consistent results.
